CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 27, 2019—Roche announced the CE-IVD mark and launch of its Navify Mutation Profiler, clinical software that provides annotation, interpretation, and clinical reporting of next-generation sequencing tests. Roche launched also its Navify Therapy Matcher, an optional clinical decision support app that further aids clinicians in linking clinically actionable mutations to relevant therapy options.
Navify Mutation Profiler simplifies how labs report on their NGS tests, according to Roche.
Pages: 1 2